Listed by the USPTO as COUGHLIN, MATTHEW P
Tech Center 1600 • Art Units: 1626 1691
This examiner grants 71% of resolved cases
COUGHLIN, MATTHEW P examines in Tech Center 1600 and Art Unit 1626. The profile covers 1,015 resolved cases and reports a 71.2% allowance rate. The median time to allowance is 892 days, providing a substantial record for evaluating expected outcome and examination duration.
The interview lift is 12.6%. The listed companies are Bristol-Myers Squibb Company, University of Florida Research Foundation Inc., and Hoffmann-La Roche Inc. The listed firms are BALLARD SPAHR LLP, Sterne, Kessler, Goldstein & Fox P.L.L.C., and BakerHostetler. These organizations identify recorded prosecution participants and may provide useful context for related matters.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18782144 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | Non-Final OA | University of Florida Research Foundation, Inc. |
| 17976651 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18909652 | NLRP3 INFLAMMASOME INHIBITORS | Non-Final OA | Novartis AG |
| 18363004 | ANTIMICROBIAL COMPOSITION COMPRISING A DIOCTYLDIMETHYLAMMONIUM COMPOUND | Non-Final OA | The Procter & Gamble Company |
| 16772768 | SUBSTITUTED AROMATIC AMINES FOR USE IN ORGANIC ELECTROLUMINESCENT DEVICES | Non-Final OA | Merck Patent GmbH |
| 18828945 | GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS | Non-Final OA | Eli Lilly and Company |
| 18375697 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS | Final Rejection | OHIO STATE INNOVATION FOUNDATION |
| 18526795 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18015746 | MONOTERPENOID AND PHENYLPROPANOID CARBONATE ESTERS AND METHODS OF THEIR MAKING AND USE AS REPELLENTS | Non-Final OA | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. |
| 18686802 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | Non-Final OA | Purdue Research Foundation |
| 18758924 | Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy | Final Rejection | Rutgers, The State University of New Jersey |
| 18963289 | PHARMACEUTICAL COMPOSITION CONTAINING FRAXETIN FOR PREVENTION OR TREATMENT OF ENDOMETRIOSIS | Non-Final OA | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 18555112 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | Final Rejection | Yale University |
| 18259606 | Metal Complexes and Methods for the Same | Non-Final OA | Colgate-Palmolive Company |
| 18873229 | TETRAHYDROPYRIDO 3,4-D PYRIMIDINE DERIVATIVES AS KRAS INHIBITORS | Non-Final OA | Bristol-Myers Squibb Company |
| 18331831 | KRAS INHIBITORS | Non-Final OA | Bristol-Myers Squibb Company |
| 18036095 | PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES | Final Rejection | Icahn School of Medicine at Mount Sinai |
| 18325264 | PROCESS FOR PRODUCING FURFURAL FROM BIOMASS | Final Rejection | UOP LLC |
| 18274293 | COMPOSITIONS AND METHODS FOR INHIBITING YAP | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18858952 | SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy71.2% of resolved applications examined by Matthew P Coughlin were allowed (1,015 resolved cases), compared with 54.6% across Art Unit 1626 over the last five years.
This examiner's interview lift is +12.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Matthew P Coughlin took 892 days on average from filing to allowance.
Matthew P Coughlin examines applications in Art Unit 1626 in Tech Center 1600 (Biotechnology & Pharmaceuticals).